Bank of America Corporation (BAC)

Bank of America's stock has slipped to $50.70, sitting 22.28% below its 52-week high of $65.23 and 7.63% below its 200-day average. The most recent move came after the October 14, 2026 report, when adjusted EPS of $0.91 missed the $1.11 estimate by 18.02% and the shares fell 4.76% in the next session. Analysts have not turned cautious: 22 of 25 rate the stock Buy, yet CleaRank's own rating is Hold with a score of 49 out of 100, because price trend and momentum are weak even though the stock looks cheap on earnings.

Bank of America reported adjusted EPS of $0.91 on October 14, 2026, against an analyst estimate of $1.11, a miss of 18.02%. The shares fell 4.76% in the first session after the report. It was the only one of the last eight reports that missed. Seven of the eight reports beat, and in three of those beats the shares still closed lower in the first session, so a beat has not guaranteed a positive reaction. The October miss matters because it came after a run of beats, and it lowered the bar the stock must clear next quarter.

The stock trades at a trailing P/E of 12.10, a discount of 26.7% to the sector median of 16.5, and a price-to-sales ratio of 3.05 against a sector median of 3.8. Its GAAP earnings per share over the last 12 months is $4.19, and the net profit margin is 26.8%. Against that, the price is 7.46% below its 50-day SMA and 7.63% below its 200-day SMA, and the 50-day average sits just 0.18% below the 200-day average. Those are the two sides of the stock today: earnings and sales multiples look modest, while the price has not regained its averages.

Return on equity is 10.73%, below the sector median of 13.8%. The stock is up 2.08% over one week but down 6.67% over one month, down 20.79% over three months and down 5.10% over one year. The stock's 1.19 beta against the S&P 500 means it tends to move more than the market, with a typical daily move of 1.60%.

Of 25 analysts with a current rating, 22 rate the stock Buy or Strong Buy, 3 rate it Hold and none rate it Sell. Three months ago 20 of 24 ratings were Buy. Recent actions include UBS keeping its Buy rating on November 2, 2026, and JP Morgan keeping its Overweight rating on October 30, 2026. Analysts expect EPS growth of 14.6% this fiscal year and 16.7% next year. CleaRank's rating of Hold is more cautious than the Wall Street consensus of Buy, mainly because of trend and momentum. Insiders made eight sales worth $37.8M over the last 18 months and no open-market purchases, although insider sales are often planned in advance or made to cover tax on vesting shares.

The base case is that the stock stays range-bound while it works back toward its moving averages. The price needs to reclaim the 20-day EMA at $51.15 and then the 50-day SMA at $54.78 before the trend can be called repaired, and that would require the next quarterly report to match or beat the estimate after the October 14, 2026 miss, when EPS of $0.91 came in 18.02% below the $1.11 forecast. The stock trades at 12.10 times trailing earnings against a sector median of 16.5, so a steady earnings trajectory would keep valuation support in place. Analysts expect EPS to rise 14.6% this year to $4.37 and 16.7% next year to $5.10, which gives the bulls a clear earnings path if the quarterly results start to match it. A further break below the 52-week low of $46.12 would weaken the case, as would another earnings shortfall. These figures describe the current setup, not a forecast of the next move.

Support sits at the 52-week low of $46.12, the nearest level below the price and the level a fall would meet first. Resistance is the 20-day EMA at $51.15, the nearest level above the price and the first hurdle a rise would meet. Above it, the 50-day SMA at $54.78 and the 200-day SMA at $54.88 sit close together and form a broader resistance zone that the price has not recovered since the earnings-driven decline. The 52-week high of $65.23 is the furthest level above the price and marks the top of the range.